E-islet 01 allogeneic human regenerative islets
EndoCell Therapeutics, Inc.
Early-stage; watch this space.
What it is
EndoCell Therapeutics' allogeneic human E-islet product is a stem-cell-derived islet-replacement approach delivered through the hepatic portal vein. A Phase 1/2a trial in adults with long-standing T1D, impaired hypoglycemia awareness, and severe hypoglycemia is recruiting in China; early human stem-cell-derived islet experience has been published, but the registered E-islet 01 trial has no posted efficacy results yet.
Editorial review: .
Most recent recorded citation date: 2026-02-26. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Insulin independence: Published early human experience with autologous/allogeneic stem-cell-derived islets exists, and the E-islet 01 trial includes insulin-independence-adjacent endpoints, but this specific registered product has no posted efficacy results yet.[2]
- Important harms and treatment burden
- Immunosuppression-free: The registered product is allogeneic cells infused into the portal vein, with no immunosuppression-free protection strategy established in the public record. Nor does the platform's autologous work clear that bar: the celebrated E-islet "cure" was a man with type 2 diabetes who was already on chronic immunosuppression for a prior kidney transplant. There is no human evidence of an E-islet graft surviving without anti-rejection drugs.[3]
- Approval and country access
- Recruiting Phase 1/2a (21 planned); no efficacy postedApproval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: The active trial follows participants for up to 5 years, but durable graft function for E-islet 01 is not yet reported.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 30 × 30 + 25 × 20 + 20 × 20 + 35 × 10 + 25 × 10 + 25 × 10 = 2650; divide by total weight 100. Unrounded weighted result: 26.5.
Published early human experience with autologous/allogeneic stem-cell-derived islets exists, and the E-islet 01 trial includes insulin-independence-adjacent endpoints, but this specific registered product has no posted efficacy results yet.[2]
The active trial follows participants for up to 5 years, but durable graft function for E-islet 01 is not yet reported.[1]
The registered product is allogeneic cells infused into the portal vein, with no immunosuppression-free protection strategy established in the public record. Nor does the platform's autologous work clear that bar: the celebrated E-islet "cure" was a man with type 2 diabetes who was already on chronic immunosuppression for a prior kidney transplant. There is no human evidence of an E-islet graft surviving without anti-rejection drugs.[3]
Portal-vein infusion is less invasive than a major implant operation but still carries the procedural burden and non-retrievability issues of intrahepatic islet transplantation.[1]
The current trial targets a narrow high-risk group: adults 18-75 with T1D, impaired hypoglycemia awareness, and severe hypoglycemia at a single listed Shanghai site.[1]
Recruiting Phase 1/2a trial with 21 planned participants; important but still early human development.[1]
The full picture
What it is
E-islet 01 is EndoCell Therapeutics' allogeneic human islet-replacement product for people with established type 1 diabetes who have impaired awareness of hypoglycemia and severe hypoglycemia.1 The public registry describes it as Allogeneic Human E-islet (E-islet 01), infused into the hepatic portal vein.1 That places it in the same broad family as donor-islet and Vertex zimislecel approaches: replacing missing insulin-producing cells rather than asking an algorithm to dose insulin around them.
Clinical status
The registered study, NCT07126873, is a Phase 1/2a, open-label, sequential trial at Shanghai Changzheng Hospital.1 It plans 21 adults aged 18-75, with follow-up to 5 years.1 The primary outcomes include safety/tolerability and the proportion of participants free of severe hypoglycemia with HbA1c improvement at 1 year after infusion.1 A live registry check on 27 August 2026 confirmed the trial is still recruiting, with primary completion expected December 2027 and study completion December 2029; no results have been posted.1
What is known so far
The strongest published signal near this program is a 2026 Lancet Diabetes & Endocrinology report of autologous and allogeneic stem-cell-derived islet therapy in three people with T1D and complete loss of endogenous beta-cell function before transplant.2 That supports the broader E-islet platform as clinically plausible, but it does not mean the registered E-islet 01 trial has proved efficacy. ClinicalTrials.gov lists the E-islet 01 study as recruiting and does not post trial results.1
The autologous case does not mean "no drugs"
The E-islet platform is best known for a 2024 Cell Discovery report — a man who stopped needing insulin 11 weeks after receiving islets grown from his own reprogrammed blood cells, and who was reported off it through the paper's 116-week follow-up. It is widely retold as a cure achieved without anti-rejection drugs. Two things are wrong with that retelling:3
- He had type 2 diabetes, not type 1 — a 59-year-old with a 25-year history of T2D. On this site, Type 2 evidence never scores a Type 1 record, and it does not score this one.
- He was already immunosuppressed. He had developed end-stage diabetic nephropathy and received a kidney transplant in 2017, which means chronic systemic anti-rejection drugs were already on board when the E-islets went in.
This is the same pattern as the CiPSC "cured with her own cells" case in Tianjin, and the lesson is the same. Autologous cells answer allo-rejection — there is nothing foreign to reject. They do not answer the autoimmunity that destroys beta cells in type 1 diabetes; a perfectly matched graft is exactly the target those memory T cells were trained on. Nobody has yet shown a stem-cell-derived islet graft of any kind — autologous or allogeneic — surviving in an untreated type 1 immune system, with the single reported exception of Sana's gene-edited UP421 patient (not verified against a primary source in this review).
Key caveats
The registry does not establish an immunosuppression-free protection strategy, and the product is infused into the portal vein rather than placed in a retrievable device.1 Until public results clarify immune regimen, C-peptide durability, insulin-use reduction, and safety, this belongs as an early pipeline cell-replacement record, not a proven cure.
Coming soon
ETA · Recruiting Phase 1/2a; primary completion estimated December 2027, study completion December 2029; no approval timing yet
- →First registered E-islet 01 safety, C-peptide, glucose, and insulin-use readouts · Trial follow-up runs through 2029 (registry-estimated completion)
Sources
- [1]A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes · Trial registry · 2025-08-17
EndoCell Therapeutics, Inc. A Safety, Tolerability, and Efficacy Study of E-islet 01 in Participants With Type 1 Diabetes. ClinicalTrials.gov NCT07126873 (last updated 2025).
- [2]Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic beta-cell function pretransplant · Peer-reviewed study · 2026-02-26
Shi Y, Feng Y, Li T, et al. Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic beta-cell function pretransplant. Lancet Diabetes Endocrinol (2026).
- [3]Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue · Peer-reviewed study · 2024-04-30 — The famous E-islet case. A 59-year-old man with a 25-year history of TYPE 2 diabetes who "developed end-stage diabetic nephropathy and underwent kidney transplantation in June of 2017" — i.e. already on chronic systemic immunosuppression when the autologous E-islets were transplanted. Type 2 evidence does not score a Type 1 record; it is cited here only to correct what the case is routinely claimed to show.
Wu J, Li T, Guo M, et al. Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue. Cell Discovery (30 April 2024). "The patient was a 59-year-old man with a 25-year history of T2D who developed end-stage diabetic nephropathy and underwent kidney transplantation in June of 2017."